ACROBiosystems社 CD3：A Promising Tumor Therapeutic Target in the Field of Bispecific Antibodies
CD3 is an important biomarker on the T-cell membrane and consists of four protein chains (CD3δ, CD3ε, CD3γ, and CD3ζ). Of these, two pairs of heterodimers（CD3δ/CD3ε, CD3γ/CD3ε）can form the TCR/CD3 complex together and be involved in the regulation of T cell antigen recognition, signal transduction, and T cell development. The intracellular region of the TCR is very short and cannot perform signal transduction independently and bispecific antibodies allow for dose control to reduce toxicity compared to CAR-T. Therefore, CD3 is a promising target for tumor therapy in the field of bispecific antibodies.
To accelerate the research and development of bispecific antibodies, ACROBiosystems has developed a series of homogeneous CD3δ/CD3ε and CD3γ/CD3ε proteins with high bioactivity. These proteins are verified as a 1:1 heterodimer by nonreductive electrophoresis and MALS respectively. In addition, customer data suggests that bispecific antibody products from ACROBiosystems can be used in applications including, but not limited to clinical pharmacokinetics, therapeutic antibody screening, identification, and characterization.
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。